Overview

Endothelin Antagonism in ANCA Vasculitis

Status:
Completed
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
Patients with vasculitis commonly develop cardiovascular disease. The reasons for this are not clear and is not adequately treated with current drugs. It is thus understand the reasons why patients with vasculitis develop cardiovascular disease in order to develop new drugs to reduced this risk. Endothelin is a chemical produced by blood vessels that contributes to the development of hypertension and cardiovascular disease Higher than normal levels of endothelin are seen in patients with vasculitis but how this contributes to cardiovascular disease in patients with vasculitis is not clear. By using drugs that block the effects of endothelin ('endothelin receptor antagonists') the investigators can hopefully reduce the risk of cardiovascular disease in patients with vasculitis. The purpose of the study is to ascertain if endothelin receptor antagonists improve blood vessel function in patients with vasculitis.
Phase:
N/A
Details
Lead Sponsor:
University of Edinburgh
Collaborator:
British Heart Foundation
Treatments:
cyclo(Trp-Asp-Pro-Val-Leu)